I agree that this site is using cookies. You can find further informations here.
X
Hirayama, A.V.
215  results:
Search for persons X
?
1

HIGH EFFICACY AND FAVORABLE SAFETY OF 3RD GENERATION CD20 C..:

Shadman, M. ; Yeung, C. ; Redman, M....
Hematological Oncology.  41 (2023)  S2 - p. 87-88 , 2023
Link: https://doi.org/10.1002/..
 
?
2

LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R MCL: PRIMARY ANA..:

Wang, M. ; Siddiqi, T. ; Gordon, L. I....
Hematological Oncology.  41 (2023)  S2 - p. 875-877 , 2023
Link: https://doi.org/10.1002/..
 
?
3

HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPH..:

Hirayama, A.V. ; Gauthier, J. ; Hay, K.A....
Hematological Oncology.  37 (2019)  S2 - p. 170-171 , 2019
Link: https://doi.org/10.1002/..
 
?
4

Durable responses after CD19‐targeted CAR‐T cell immunother..:

Gauthier, J. ; Hirayama, A.V. ; Hay, K.A....
Hematological Oncology.  37 (2019)  S2 - p. 168-170 , 2019
Link: https://doi.org/10.1002/..
 
?
5

SAFETY OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN ADULT..:

Shadman, M. ; Gauthier, J. ; Hay, K.A....
Hematological Oncology.  37 (2019)  S2 - p. 313-314 , 2019
Link: https://doi.org/10.1002/..
 
?
6

Identification and Prediction of Severe Hematologic Toxicit..:

Liang, Emily C. ; Albittar, Aya ; Portuguese, Andrew J....
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S180-S181 , 2024
Link: https://doi.org/10.1016/..
 
?
7

Early Prediction of Severe Icans after CD19 CAR T-Cell Ther..:

Huang, Jennifer J ; Liang, Emily C. ; Albittar, Aya...
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S193-S194 , 2024
Link: https://doi.org/10.1016/..
 
?
8

Answering the "Doctor, can CAR-T therapy cause cancer?" que..:

Banerjee, Rahul ; Poh, Christina ; Hirayama, Alexandre V....
Blood Advances.  8 (2024)  4 - p. 895-898 , 2024
Link: https://doi.org/10.1182/..
 
?
9

Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) with R..:

Palomba, M. Lia ; Siddiqi, Tanya ; Gordon, Leo I....
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S14 , 2024
Link: https://doi.org/10.1016/..
 
?
10

Timing of anti–PD-L1 antibody initiation affects efficacy/t..:

Hirayama, Alexandre V. ; Kimble, Erik L. ; Wright, Jocelyn H....
Blood Advances.  8 (2024)  2 - p. 453-467 , 2024
Link: https://doi.org/10.1182/..
 
?
11

Acalabrutinib in Combination with Anti-CD19 Chimeric Antige..:

Poh, Christina ; Chow, Victor A ; Lynch, Ryan C...
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S33 , 2024
Link: https://doi.org/10.1016/..
 
?
12

T-Cell Large Granular Lymphocyte Population Involving Chime..:

Albittar, Aya ; Torabi, Alireza ; Liang, Emily C....
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S176 , 2024
Link: https://doi.org/10.1016/..
 
?
13

Identification of Predictors of CRS and Neurotoxicity Durat..:

Albittar, Aya ; Voutsinas, Jenna M ; Portuguese, Andrew J....
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S175 , 2024
Link: https://doi.org/10.1016/..
 
?
14

qPCR assay for detection of Woodchuck Hepatitis Virus Post-..:

Pullarkat, Shalini ; Black, Graeme ; Bleakley, Marie...
PLOS ONE.  19 (2024)  6 - p. e0303057 , 2024
Link: https://doi.org/10.1371/..
 
?
15

Safety and Efficacy of Fully-Human-Binder-Bearing CD19 CAR ..:

Huang, Jennifer J. ; Hirayama, Alexandre V ; Jaeger-Ruckstuhl, Carla A...
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S186 , 2024
Link: https://doi.org/10.1016/..
 
1-15